The key products to be generated after R&D would be skin creams designed to treat patients with damaged skin caused by medicines to treat disease. Chemotherapeutic drugs are used for a variety of medical purposes, including cancer, kidney failure, and sever immune deficiencies. Unfortunately, drugs that fit in this class and other classes of drugs cause skin damage, including eczema, psoriasis, skin lesions, etc. Currently, there are minimal effective therapeutic options to improve the quality of skin in these patients. We are developing novel skin creams that promote repair in the skin through targeting stem and progenitors that replace damaged skin cells. Furthermore, individuals that work outdoors for long periods of time have limited products available to provide protection from UV exposure (e.g. wide brim hats, UV sun block). Additionally, patients who suffer from Vitiligo, a condition that causes depigmentation of parts of the skin, have limited treatment options, including steroidal creams. Therefore, we are developing products that target this patient population. We plan to continue R&D in Wuhan, China in order to establish partnerships in China to facilitate bringing these products to the Chinese market.